EP3294273A4 - Préparations d'anticorps anti-interleukines à administrer dans la lumière du tractus intestinal au moyen d'un dispositif d'administration pharmacologique à avaler - Google Patents

Préparations d'anticorps anti-interleukines à administrer dans la lumière du tractus intestinal au moyen d'un dispositif d'administration pharmacologique à avaler Download PDF

Info

Publication number
EP3294273A4
EP3294273A4 EP16793347.2A EP16793347A EP3294273A4 EP 3294273 A4 EP3294273 A4 EP 3294273A4 EP 16793347 A EP16793347 A EP 16793347A EP 3294273 A4 EP3294273 A4 EP 3294273A4
Authority
EP
European Patent Office
Prior art keywords
lumen
intestinal tract
antibody preparations
delivery device
swallowable drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16793347.2A
Other languages
German (de)
English (en)
Other versions
EP3294273A1 (fr
Inventor
Mir Imran
Radhika KORUPOLU
Elaine TO
Mir Hashim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rani Therapeutics LLC
Original Assignee
Incube Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incube Laboratories LLC filed Critical Incube Laboratories LLC
Publication of EP3294273A1 publication Critical patent/EP3294273A1/fr
Publication of EP3294273A4 publication Critical patent/EP3294273A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP16793347.2A 2015-05-08 2016-05-09 Préparations d'anticorps anti-interleukines à administrer dans la lumière du tractus intestinal au moyen d'un dispositif d'administration pharmacologique à avaler Pending EP3294273A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562159134P 2015-05-08 2015-05-08
PCT/US2016/031548 WO2016183040A1 (fr) 2015-05-08 2016-05-09 Préparations d'anticorps anti-interleukines à administrer dans la lumière du tractus intestinal au moyen d'un dispositif d'administration pharmacologique à avaler

Publications (2)

Publication Number Publication Date
EP3294273A1 EP3294273A1 (fr) 2018-03-21
EP3294273A4 true EP3294273A4 (fr) 2018-12-05

Family

ID=57248408

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16793347.2A Pending EP3294273A4 (fr) 2015-05-08 2016-05-09 Préparations d'anticorps anti-interleukines à administrer dans la lumière du tractus intestinal au moyen d'un dispositif d'administration pharmacologique à avaler

Country Status (6)

Country Link
EP (1) EP3294273A4 (fr)
JP (2) JP7185401B2 (fr)
CN (1) CN107835682A (fr)
AU (2) AU2016261599B2 (fr)
CA (1) CA2984422C (fr)
WO (1) WO2016183040A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10689460B2 (en) 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
AU2016320867B2 (en) * 2015-09-08 2023-03-30 Rani Therapeutics, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2018112256A1 (fr) * 2016-12-14 2018-06-21 Progenity Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur d'il-1
JP2022516513A (ja) * 2018-12-31 2022-02-28 ラニ セラピューティクス， エルエルシー 嚥下可能薬物送達デバイスを使用する腸管の管腔への送達のための治療剤調製物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031770A2 (fr) * 2006-09-12 2008-03-20 Cosmo Technologies Ltd Compositions pharmaceutiques pour administration de substances protéiques par voie buccale ou anale
WO2009063222A2 (fr) * 2007-11-15 2009-05-22 Ucl Business Plc Compositions solides
US20120027775A1 (en) * 2010-08-02 2012-02-02 Advanced Technologies And Regenerative Medicine, Llc Absorbable peg-based hydrogels
WO2014066468A1 (fr) * 2012-10-25 2014-05-01 Medimmune, Llc Formulation d'anticorps, stable, à faible viscosité
WO2015176031A2 (fr) * 2014-05-15 2015-11-19 Incube Labs, Llc Compositions pharmaceutiques et procédés de fabrication de masses solides comprenant des polypeptides et/ou des protéines

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6024767B2 (ja) * 1979-08-24 1985-06-14 塩野義製薬株式会社 腸溶性硬カプセル剤
WO2006052660A2 (fr) * 2004-11-04 2006-05-18 Childrens Hospital Los Angeles Research Institute Blocage du recepteur il-7 pour supprimer l'immunite
US8721620B2 (en) * 2009-12-24 2014-05-13 Rani Therapeutics, Llc Swallowable drug delivery device and methods of drug delivery
AU2010336330B2 (en) * 2009-12-24 2016-04-28 Rani Therapeutics, Llc Swallowable drug delivery device and methods of drug delivery
US8980822B2 (en) * 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9149617B2 (en) * 2010-12-23 2015-10-06 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
AU2012275417B9 (en) * 2011-06-29 2017-08-31 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
EP3653224A1 (fr) * 2011-06-29 2020-05-20 Rani Therapeutics, LLC Préparations d'agent thérapeutique pour l'administration dans une lumière du tractus intestinal à l'aide d'un dispositif d'administration de médicaments à avaler
US20150064241A1 (en) * 2013-09-05 2015-03-05 Google Inc. Delivery of Functionalized Particles
CA2983337A1 (fr) * 2015-05-01 2016-11-10 Incube Labs, Llc Compositions pharmaceutiques et procedes de fabrication de masses solides comprenant des polypeptides et/ou des proteines

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031770A2 (fr) * 2006-09-12 2008-03-20 Cosmo Technologies Ltd Compositions pharmaceutiques pour administration de substances protéiques par voie buccale ou anale
WO2009063222A2 (fr) * 2007-11-15 2009-05-22 Ucl Business Plc Compositions solides
US20120027775A1 (en) * 2010-08-02 2012-02-02 Advanced Technologies And Regenerative Medicine, Llc Absorbable peg-based hydrogels
WO2014066468A1 (fr) * 2012-10-25 2014-05-01 Medimmune, Llc Formulation d'anticorps, stable, à faible viscosité
WO2015176031A2 (fr) * 2014-05-15 2015-11-19 Incube Labs, Llc Compositions pharmaceutiques et procédés de fabrication de masses solides comprenant des polypeptides et/ou des protéines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LONNBERG ET AL: "Targeting of interleukin-17 in the treatment of psoriasis", CLINICAL, COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 1 September 2014 (2014-09-01), pages 251, XP055328086, DOI: 10.2147/CCID.S67534 *

Also Published As

Publication number Publication date
AU2021269453A1 (en) 2021-12-16
JP7185401B2 (ja) 2022-12-07
AU2016261599A1 (en) 2017-11-23
CA2984422A1 (fr) 2016-11-17
AU2016261599B2 (en) 2021-08-26
CA2984422C (fr) 2023-10-17
JP7232805B2 (ja) 2023-03-03
JP2018520995A (ja) 2018-08-02
JP2021042239A (ja) 2021-03-18
EP3294273A1 (fr) 2018-03-21
CN107835682A (zh) 2018-03-23
WO2016183040A1 (fr) 2016-11-17

Similar Documents

Publication Publication Date Title
EP3706720A4 (fr) Préparations de facteurs de coagulation à administrer dans un tissu du tractus intestinal au moyen d'un dispositif d'administration de médicament à avaler
EP3316872A4 (fr) Préparations d'agent thérapeutique à administrer dans une lumière du tractus intestinal au moyen d'un dispositif d'administration de médicament avalable
EP3347050A4 (fr) Préparations d'anticorps contre pcsk9 à administrer dans une lumière du tractus intestinal au moyen d'un dispositif d'administration de médicament à avaler
PL2726091T3 (pl) Preparaty lecznicze dostarczane do kanału przewodu jelitowego za pomocą połykalnego urządzenia dostarczającego lek
EP3615113A4 (fr) Mécanisme de commande d'inhalateur médical
EP3970767A4 (fr) Dispositif de perfusion de médicament
EP3302265A4 (fr) Capsule d'administration d'un médicament
EP3437676A4 (fr) Dispositif d'administration de médicament liquide
EP4003458A4 (fr) Dispositif de perfusion de médicament à entraînement unilatéral
EP3962516A4 (fr) Préparations de facteurs de coagulation à administrer dans un tissu du tractus intestinal au moyen d'un dispositif d'administration de médicament à avaler
EP3294273A4 (fr) Préparations d'anticorps anti-interleukines à administrer dans la lumière du tractus intestinal au moyen d'un dispositif d'administration pharmacologique à avaler
EP3445416A4 (fr) Système d'administration entérale de médicaments
EP3905999A4 (fr) Préparations d'agent thérapeutique à administrer dans une lumière du tractus intestinal au moyen d'un dispositif d'administration de médicament à avaler
EP3260148A4 (fr) Dispositif d'administration de médicament liquide
EP3520843A4 (fr) Dispositif d'administration de médicament liquide
EP3263155A4 (fr) Dispositif d'administration de solution médicamenteuse
EP3597235A4 (fr) Dispositif d'injection de liquide médicinal
EP3900727A4 (fr) Mécanisme d'immunité et médicament thérapeutique pour maladies gastro-intestinales
IL279127A (en) Dispensing devices for drug administration
EP3925643A4 (fr) Appareil d'administration de médicament liquide
EP3801703A4 (fr) Système d'administration de médicament intégré dans le tissu
EP3925645A4 (fr) Appareil d'administration de médicament liquidev
EP3846885B8 (fr) Dispositif d'administration de médicaments
EP3351286A4 (fr) Dispositif d'administration de solution de médicament
EP3661576A4 (fr) Nébuliseur médical pour administration rapide de médicament

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171027

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20181029

RIC1 Information provided on ipc code assigned before grant

Ipc: A61F 13/00 20060101ALI20181023BHEP

Ipc: A61K 9/20 20060101AFI20181023BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20201202

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RANI THERAPEUTICS, LLC

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230524